Laws and Labels: A Regulatory View of Biosimilars
Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.
You may also like:
The annual Hospital Management Asia (HMA) conference brings together hospital and healthcare managers from across the Asia Pacific region to share best practices and ideas for quality improvement. Healthcare information technology...
February is American Heart Month. Follow events and discussions at #HeartMonth. Medication safety can sometimes be a tightrope walk of balancing var...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!